Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.83
BCRX's Cash-to-Debt is ranked lower than
73% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. BCRX: 1.83 )
Ranked among companies with meaningful Cash-to-Debt only.
BCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.94  Med: No Debt Max: 11087.67
Current: 1.83
0.94
11087.67
Equity-to-Asset 0.30
BCRX's Equity-to-Asset is ranked lower than
85% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BCRX: 0.30 )
Ranked among companies with meaningful Equity-to-Asset only.
BCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.23  Med: 0.69 Max: 0.98
Current: 0.3
-0.23
0.98
Piotroski F-Score: 2
Altman Z-Score: -3.28
Beneish M-Score: -2.52
WACC vs ROIC
18.01%
-676.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -129.95
BCRX's Operating Margin % is ranked lower than
54% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. BCRX: -129.95 )
Ranked among companies with meaningful Operating Margin % only.
BCRX' s Operating Margin % Range Over the Past 10 Years
Min: -336.35  Med: -105.32 Max: -18.42
Current: -129.95
-336.35
-18.42
Net Margin % -150.25
BCRX's Net Margin % is ranked lower than
56% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. BCRX: -150.25 )
Ranked among companies with meaningful Net Margin % only.
BCRX' s Net Margin % Range Over the Past 10 Years
Min: -332.08  Med: -118.9 Max: -18.03
Current: -150.25
-332.08
-18.03
ROE % -272.79
BCRX's ROE % is ranked lower than
93% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. BCRX: -272.79 )
Ranked among companies with meaningful ROE % only.
BCRX' s ROE % Range Over the Past 10 Years
Min: -544.61  Med: -69.75 Max: -20.28
Current: -272.79
-544.61
-20.28
ROA % -46.91
BCRX's ROA % is ranked lower than
63% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. BCRX: -46.91 )
Ranked among companies with meaningful ROA % only.
BCRX' s ROA % Range Over the Past 10 Years
Min: -59.43  Med: -40.93 Max: -11.86
Current: -46.91
-59.43
-11.86
ROC (Joel Greenblatt) % -408.49
BCRX's ROC (Joel Greenblatt) % is ranked lower than
51% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. BCRX: -408.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15669.01  Med: -948.36 Max: -202.66
Current: -408.49
-15669.01
-202.66
3-Year Revenue Growth Rate 4.50
BCRX's 3-Year Revenue Growth Rate is ranked higher than
52% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BCRX: 4.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -70.7  Med: -3.15 Max: 528
Current: 4.5
-70.7
528
3-Year EBITDA Growth Rate 13.00
BCRX's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. BCRX: 13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.9  Med: -5.7 Max: 63.7
Current: 13
-41.9
63.7
3-Year EPS without NRI Growth Rate 10.90
BCRX's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. BCRX: 10.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.4  Med: -5.7 Max: 52.9
Current: 10.9
-38.4
52.9
GuruFocus has detected 6 Warning Signs with Biocryst Pharmaceuticals Inc $BCRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BCRX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:DVAX, NAS:ANAB, NAS:ARNA, NAS:MCRB, NAS:BOLD, NAS:GERN, NAS:RARX, NAS:ADAP, NAS:PGNX, NAS:ITCI, NAS:SYRS, NAS:MYOK, NAS:ACIU, NAS:CALA, NAS:BLCM, NAS:IMGN, NAS:AVDL, NAS:CTMX, NAS:NTLA, NAS:GLYC » details
Traded in other countries:BO1.Germany,
Headquarter Location:USA
Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Biocryst Pharmaceuticals is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modelling, and medical chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Ratios

vs
industry
vs
history
PB Ratio 11.75
BCRX's PB Ratio is ranked lower than
86% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. BCRX: 11.75 )
Ranked among companies with meaningful PB Ratio only.
BCRX' s PB Ratio Range Over the Past 10 Years
Min: 1.05  Med: 9.01 Max: 339.52
Current: 11.75
1.05
339.52
PS Ratio 14.64
BCRX's PS Ratio is ranked lower than
55% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. BCRX: 14.64 )
Ranked among companies with meaningful PS Ratio only.
BCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.72  Med: 7.01 Max: 174.76
Current: 14.64
0.72
174.76
Current Ratio 1.94
BCRX's Current Ratio is ranked lower than
76% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BCRX: 1.94 )
Ranked among companies with meaningful Current Ratio only.
BCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.8  Med: 7.13 Max: 39.53
Current: 1.94
0.8
39.53
Quick Ratio 1.93
BCRX's Quick Ratio is ranked lower than
71% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BCRX: 1.93 )
Ranked among companies with meaningful Quick Ratio only.
BCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.77  Med: 7.13 Max: 39.53
Current: 1.93
0.77
39.53
Days Inventory 182.37
BCRX's Days Inventory is ranked lower than
67% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. BCRX: 182.37 )
Ranked among companies with meaningful Days Inventory only.
BCRX' s Days Inventory Range Over the Past 10 Years
Min: 142.81  Med: 307.94 Max: 15234.51
Current: 182.37
142.81
15234.51
Days Sales Outstanding 112.72
BCRX's Days Sales Outstanding is ranked lower than
75% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. BCRX: 112.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.54  Med: 131.08 Max: 200.48
Current: 112.72
44.54
200.48
Days Payable 680.06
BCRX's Days Payable is ranked higher than
98% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. BCRX: 680.06 )
Ranked among companies with meaningful Days Payable only.
BCRX' s Days Payable Range Over the Past 10 Years
Min: 577.32  Med: 8523.65 Max: 34806.57
Current: 680.06
577.32
34806.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.70
BCRX's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. BCRX: -7.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.4  Med: -8.9 Max: -0.6
Current: -7.7
-20.4
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 61.20
BCRX's Price-to-Net-Cash is ranked lower than
94% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. BCRX: 61.20 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BCRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.61  Med: 12.34 Max: 315
Current: 61.2
0.61
315
Price-to-Net-Current-Asset-Value 20.40
BCRX's Price-to-Net-Current-Asset-Value is ranked lower than
82% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. BCRX: 20.40 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BCRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.59  Med: 6.34 Max: 87.69
Current: 20.4
0.59
87.69
Price-to-Tangible-Book 11.75
BCRX's Price-to-Tangible-Book is ranked lower than
80% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. BCRX: 11.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.33  Med: 4.7 Max: 301.43
Current: 11.75
0.33
301.43
Price-to-Median-PS-Value 2.09
BCRX's Price-to-Median-PS-Value is ranked lower than
82% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BCRX: 2.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 3.53 Max: 418.75
Current: 2.09
0.13
418.75
Earnings Yield (Greenblatt) % -8.81
BCRX's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. BCRX: -8.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1150.2  Med: -15.25 Max: 1563.9
Current: -8.81
-1150.2
1563.9

More Statistics

Revenue (TTM) (Mil) $30.97
EPS (TTM) $ -0.63
Beta2.68
Short Percentage of Float20.27%
52-Week Range $2.60 - 9.25
Shares Outstanding (Mil)80.42

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 33 33 13
EPS ($) -0.75 -0.64 -1.05
EPS without NRI ($) -0.75 -0.64 -1.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
BioCryst to Present at the JMP Securities 2017 Life Sciences Conference Jun 13 2017 
BioCryst Announces RAPIVAB® Pediatric sNDA Acceptance Jun 05 2017 
BioCryst to Present at the Jefferies 2017 Global Healthcare Conference May 31 2017 
Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals, Inc. May 30 2017 
BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial May 25 2017 
BioCryst to Present at the Bank of America Merrill Lynch 2017 Health Care Conference May 09 2017 
BioCryst Reports First Quarter 2017 Financial Results May 04 2017 
BioCryst to Announce First Quarter 2017 Financial Results May 4 Apr 24 2017 
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks Apr 12 2017 
BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan Apr 03 2017 

More From Other Websites
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US :... Jun 21 2017
ETFs with exposure to BioCryst Pharmaceuticals, Inc. : June 16, 2017 Jun 16 2017
Biotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals... Jun 15 2017
BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Jun 14 2017
BioCryst to Present at the JMP Securities 2017 Life Sciences Conference Jun 13 2017
Down 24.6%, is BioCryst Pharmaceuticals Stock Now a Buy? Jun 06 2017
Flu therapy from RTP's BioCryst could be available for kids next season Jun 06 2017
BioCryst Announces RAPIVAB® Pediatric sNDA Acceptance Jun 05 2017
BioCryst to Present at the Jefferies 2017 Global Healthcare Conference May 31 2017
Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals, Inc. May 30 2017
Why Zoe's Kitchen, Beazer Homes, and BioCryst Pharmaceuticals Slumped Today May 26 2017
BioCryst and Aerie Pharmaceuticals' Shares Swell on Positive Study Results May 26 2017
Why BioCryst Pharmaceuticals Stock Caught Fire Today May 25 2017
Stocks rise for Aerie, BioCryst following positive trial results May 25 2017
Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring May 25 2017
BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial May 25 2017
Shire's swelling disorder drug moves closer to U.S. approval May 18 2017
Implied Volatility Surging for BioCryst (BCRX) Stock Options May 16 2017
Edited Transcript of BCRX earnings conference call or presentation 4-May-17 3:00pm GMT May 11 2017
BioCryst to Present at the Bank of America Merrill Lynch 2017 Health Care Conference May 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}